Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 9:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Soft Tissue Clear all
Completed Phase 1 Interventional

ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated, Incurable Ewing Sarcoma

NCT02044120
View directory record Official record
Conditions
Ewing Sarcoma
Interventions
niraparib, Temozolomide, Irinotecan
Drug
Lead sponsor
Sarcoma Alliance for Research through Collaboration
Other
Eligibility
13 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
4
States / cities
Los Angeles, California • Bethesda, Maryland • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Sep 10, 2026, 9:33 AM EDT
Completed Phase 1 Interventional

A Study of Azenosertib (ZN-c3) in Combination With Gemcitabine in Subjects With Osteosarcoma

NCT04833582
View directory record Official record
Conditions
Osteosarcoma
Interventions
Azenosertib, Gemcitabine
Drug
Lead sponsor
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Industry
Eligibility
12 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
12
States / cities
Los Angeles, California • Oakland, California • Santa Monica, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Sep 10, 2026, 9:33 AM EDT
Completed Phase 1 Interventional

Sirolimus in Treating Patients With HIV-Related Kaposi's Sarcoma

NCT00450320
View directory record Official record
Conditions
Sarcoma
Interventions
sirolimus
Drug
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
3
States / cities
La Jolla, California • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 28, 2014 · Synced Sep 10, 2026, 9:33 AM EDT
Completed Phase 3 Interventional Results available

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

NCT00538850
View directory record Official record
Conditions
Cancer
Interventions
Fentanyl sublingual spray, Placebo
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Chandler, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Sep 10, 2026, 9:33 AM EDT
Not yet recruiting No phase listed Observational Accepts healthy volunteers

Anastrozole Adjuvant Trial - Study of Anastrozole Compared to NOLVADEX (Tamoxifen Citrate) for Adjuvant Treatment of Early Breast Cancer Clinical Studies), Adjunct Cytotoxic Chemotherapy and Malignant Joint Tumor

NCT06154590
View directory record Official record
Conditions
Metastatic Breast Cancer, Tumor, Muscle Neoplasms, Chronic Pain
Interventions
Method(s)1 Attribution, Method(s)2 Attribution,
Drug
Lead sponsor
DR. DIANE CHISESI NFS. MD. PHD.
Other
Eligibility
44 Years to 59 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Colorado Springs, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 3, 2023 · Synced Sep 10, 2026, 9:33 AM EDT
Completed Phase 2 Interventional

Phase II Study of Intravenous Novantrone(R) in the Treatment of AIDS Related Kaposi's Sarcoma

NCT00002259
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
Mitoxantrone hydrochloride
Drug
Lead sponsor
Lederle Laboratories
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 10, 2026, 9:33 AM EDT
Completed Phase 2 Interventional Results available

Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery

NCT00309946
View directory record Official record
Conditions
Advanced Malignant Mesothelioma, Epithelial Mesothelioma, Localized Malignant Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatous Mesothelioma
Interventions
cediranib maleate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 30, 2014 · Synced Sep 10, 2026, 9:33 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors

NCT03899792
View directory record Official record
Conditions
Medullary Thyroid Cancer, Infantile Myofibromatosis, Infantile Fibrosarcoma, Papillary Thyroid Cancer, Soft Tissue Sarcoma
Interventions
Selpercatinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Months to 21 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
12
States / cities
Los Angeles, California • Aurora, Colorado • Orlando, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Sep 10, 2026, 9:33 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

NCT02567435
View directory record Official record
Conditions
Alveolar Rhabdomyosarcoma, Botryoid-Type Embryonal Rhabdomyosarcoma, Embryonal Rhabdomyosarcoma, Rhabdomyosarcoma, Sclerosing Rhabdomyosarcoma, Spindle Cell Rhabdomyosarcoma
Interventions
Cyclophosphamide, Dactinomycin, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Questionnaire Administration, Radiation Therapy, Temsirolimus, Vincristine Sulfate, Vinorelbine
Drug · Biological · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 40 Years
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
355
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 210 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 10, 2026, 9:33 AM EDT
Completed Phase 1 Interventional

Phase 1 Study of Anti-OX40 in Patients With Advanced Cancer

NCT01644968
View directory record Official record
Conditions
Advanced Cancer
Interventions
Cohort 1 anti-OX40, Cohort 2 anti-OX40, Cohort 3 anti-OX40, Tetanus Day 29, Tetanus Day 1, KLH Day 1, KLH Day 29
Drug · Biological
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2017
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 16, 2022 · Synced Sep 10, 2026, 9:33 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of Safety, Pharmacokinetics, and Efficacy of Proellex Administered Vaginally in Women With Uterine Fibroids

NCT01451424
View directory record Official record
Conditions
Uterine Fibroids
Interventions
Proellex
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 47 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Miami Gardens, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 28, 2014 · Synced Sep 10, 2026, 9:33 AM EDT
Approved For Marketing No phase listed Expanded access

Expanded Access Program for Asfotase Alfa Treatment for Patients With Infantile- or Juvenile-onset Hypophosphatasia (HPP)

NCT02496689
View directory record Official record
Conditions
Hypophosphatasia
Interventions
asfotase alfa
Biological
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
U.S. locations
2
States / cities
Lakewood, Colorado • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 28, 2019 · Synced Sep 10, 2026, 9:33 AM EDT
Completed Phase 2 Interventional

New Therapeutic Strategies for Patients With Ewing's Sarcoma Family of Tumors, High Risk Rhabdomyosarcoma, and Neuroblastoma

NCT00001335
View directory record Official record
Conditions
Ewing's Sarcoma, Neuroblastoma, Rhabdomyosarcoma
Interventions
ADR-529, Topotecan, G-CSF
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 10, 2026, 9:33 AM EDT
Completed No phase listed Observational

Chemotherapy-induced Symptoms in Sarcoma Patients and the Impact of Tumor Burden

NCT01136824
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
Questionnaires
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 26, 2016 · Synced Sep 10, 2026, 9:33 AM EDT
Recruiting Not applicable Interventional

Exercise and Soft Tissue Sarcoma

NCT04921917
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
neoadjuvant exercise therapy
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Sep 10, 2026, 9:33 AM EDT
Completed Phase 2 Interventional Results available

Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)

NCT03441360
View directory record Official record
Conditions
Relapsed/Refractory Rhabdomyosarcoma, Non-rhabdomyosarcoma Soft Tissue Sarcoma, Ewing Sarcoma
Interventions
Eribulin mesylate
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
12 Months to 18 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
41
States / cities
Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 36 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2022 · Synced Sep 10, 2026, 9:33 AM EDT
Recruiting Not applicable Interventional

Autologous Fresh Fat Grafting Followed by Autologous Cryopreserved Fat Grafting

NCT06747715
View directory record Official record
Conditions
Facial Defect
Interventions
Serial Fat Grafting Fresh followed by Cryopreserved Fat
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Sep 10, 2026, 9:33 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

The Efficacy of Liposomal Bupivacaine in Ultrasound Guided Supraclavicular Nerve Blocks for Hand and Wrist Surgery

NCT06806410
View directory record Official record
Conditions
Hand Surgery, Wrist Surgery, Elbow Surgery, Fracture Fixation, Dupuytren Contracture, Finger Fracture, Wrist Arthropathy, Distal Radius Fracture
Interventions
Liposomal bupivacaine (LB), Dexamethasone
Drug
Lead sponsor
St. Luke's Hospital, Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Bethlehem, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Sep 10, 2026, 9:33 AM EDT
Completed Not applicable Interventional Results available

A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.

NCT00428220
View directory record Official record
Conditions
Metastatic Breast Cancer, Advanced Breast Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Renal Cell Cancer, Non-Small Cell Lung Cancer, Thyroid Cancer, Advanced/Metastatic Non-Small Cell Lung Cancer, Advanced Gastric Cancer, Gastrointestinal Stromal Tumor, Hepatocellular Carcinoma, Pancreatic Islet Cell Carcinoma, Pancreatic Neuroendocrine Tumor
Interventions
sunitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
15
States / cities
Atlanta, Georgia • Maywood, Illinois • Iowa City, Iowa + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2019 · Synced Sep 10, 2026, 9:33 AM EDT
Not yet recruiting Not applicable Interventional

Transmucosal Uterosacral Electrical Stimulation for Pelvic Pain Relief

NCT07501676
View directory record Official record
Conditions
Postoperative Pain After Uterine Fibroid Embolization, Uterine Fibroids (UF), Uterine Fibroids, Pelvic Pain, Pain Management
Interventions
TUNES (Transmucosal Uterosacral Electrical Stimulation), Sham TUNES Device
Device
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
28 Years to 52 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Sep 10, 2026, 9:33 AM EDT
Not yet recruiting No phase listed Observational

Understanding Engagement Trends in Chondrosarcoma Clinical Trials

NCT06029478
View directory record Official record
Conditions
Chondrosarcoma
Interventions
Not listed
Lead sponsor
Power Life Sciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Sep 10, 2026, 9:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Instrument Assisted Soft Tissue Mobilization Effect on Blood Flow

NCT04785079
View directory record Official record
Conditions
Asymptomatic Condition
Interventions
Graston Instrument assisted Soft tissue Mobilization
Procedure
Lead sponsor
Florida Gulf Coast University
Other
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Fort Myers, Florida
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Sep 10, 2026, 9:33 AM EDT
Terminated Early Phase 1 Interventional

Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors

NCT02080416
View directory record Official record
Conditions
Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Kaposi Sarcoma, Gastric Cancer, Nasopharyngeal Cancer, EBV, Castleman Disease
Interventions
Nelfinavir
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 9, 2016 · Synced Sep 10, 2026, 9:33 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Asfotase Alfa in Juvenile Patients With Hypophosphatasia (HPP)

NCT00952484
View directory record Official record
Conditions
Hypophosphatasia (HPP)
Interventions
asfotase alfa
Biological
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
5 Years to 12 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 31, 2019 · Synced Sep 10, 2026, 9:33 AM EDT